SYBX earnings analysis
What we found in SYBX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Synlogic remains a non-revenue shell with $0 of quarterly revenue and a $1.012 million operating loss, which widened by $0.235 million year over year. Cash burn moderated to $1.485 million in the first six months, but cash declined to $13.183 million and the company continues to rely on strategic alternatives rather than operating growth. The Caldera merger and approximately $278.0 million financing could provide a strategic reset, but closing conditions, substantial dilution to an expected 2.3% ownership stake and continued profitability uncertainty are material risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue remains nonexistent
- Revenue remained $0 in both the three and six months ended June 30, 2026 and June 30, 2025. The Company states it has not generated product revenue since inception and does not expect to generate any product revenue.
- Operating losses widened
- Quarterly operating loss increased to $1.012 million from $0.777 million year over year, a deterioration of $0.235 million. Six-month operating loss was $2.331 million versus $1.675 million, worsening by $0.656 million.
- Warrant gain lifted six-month EPS
- Diluted EPS was $(0.04) in the quarter, unchanged from $(0.04) a year earlier. For the six months, diluted EPS improved to $0.01 from $(0.02), primarily reflecting a $2.221 million gain from remeasurement of the purchase warrant liability.
- Cash burn moderated
- Cash and cash equivalents declined to $13.183 million at June 30, 2026 from $14.668 million at December 31, 2025. Net cash used in operating activities was $1.485 million for the six months, improved from $2.000 million in the prior-year period.
- Strategic review increased costs
- General and administrative expense was $0.8 million in each quarterly comparison, while six-month G&A increased to $1.892 million from $1.636 million due primarily to higher professional-services costs. Restructuring charges rose to $0.2 million for the quarter and $0.4 million for the six months, versus a $0.01 million gain and $0.03 million of charges, respectively, in the prior-year periods.
- Merger provides strategic reset
- The proposed Caldera merger is paired with approximately $278.0 million of financing. Assuming closing, existing Synlogic equityholders are expected to own approximately 2.3% of the combined company, while the combined company is expected to focus on Caldera's CLD-423 program.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Merger closing and dilution risk
- The newly disclosed Caldera merger remains conditional on stockholder approvals, an effective Form S-4 registration statement and other closing conditions. If completed under stated assumptions, pre-merger Synlogic equityholders would own approximately 2.3% of the combined company, creating substantial dilution.
- Long-term profitability remains uncertain
- A new risk factor states the post-merger company may incur losses for at least the next several years and may never achieve profitability. Synlogic had an accumulated deficit of $442.5 million at June 30, 2026 and reported $0 of revenue for the quarter.
- Expanded warrant dilution overhang
- The July 2026 warrant amendment reduced the exercise price on warrants covering 7,394,363 shares to $0.70 per share and removed holders' cash-redemption rights in a fundamental transaction. The large warrant overhang may increase dilution and transaction-related capitalization uncertainty.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.04
- Segment
- Discovery and development of Synthetic Biotics: revenue $0 for the three and six months ended June 30, 2026; the Company operates as one segment.
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management expects expenses to remain roughly the same in the near term, expects no product revenue, and believes $13.2 million of cash and cash equivalents at June 30, 2026 will fund operations at current levels for at least 12 months. The post-period Caldera transaction includes anticipated financing proceeds of approximately $278.0 million, but this is transaction financing rather than operating guidance.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 14, 2026
- Synlogic, Inc. reported no revenue for Q1 2026, maintaining a trend of no operational income. The net income increased to $0.05 per share from $0.03 per share in Q1 2025, driven primarily by a $1.9 million gain on the…
- 10-K · April 30, 2026
- Synlogic, Inc. has transitioned from a clinical research model to a non-operating public shell while seeking strategic alternatives, contributing to its cessation of operational activities, including the halt of its…
- 10-K · March 12, 2026
- Synlogic has wound down clinical operations after discontinuing its pivotal Synpheny-3 study (Feb 2024) and has repositioned as a non‑operating public shell pursuing strategic alternatives (merger/sale). The company was…
- 10-Q · August 7, 2025
- Synlogic reported Q2 (three months ended June 30, 2025) revenue of $0 and GAAP net loss of $0.529 million (EPS -$0.04), versus net income of $3.078 million (EPS $0.25) in the year-ago quarter. Operating expenses were…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SYBX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever